Endothelin-A Receptor Antagonist–Mediated Vasodilatation Is Attenuated by Inhibition of Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade | Zendy

Marianne C. Verhaar | Zendy; Fiona E. Strachan | Zendy; David E. Newby | Zendy; Nicholas L. Cruden | Zendy; Hein A. Koomans | Zendy; Ton J. Rabelink | Zendy; David J. Webb | Zendy

Open Access

Endothelin-A Receptor Antagonist–Mediated Vasodilatation Is Attenuated by Inhibition of Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade

Author(s) -

Marianne C. Verhaar,

Fiona E. Strachan,

David E. Newby,

Nicholas L. Cruden,

Hein A. Koomans,

Ton J. Rabelink,

David J. Webb

Publication year - 1998

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.97.8.752

Subject(s) - vasodilation , vasoconstriction , medicine , nitric oxide , endothelin receptor , endocrinology , receptor antagonist , endothelin receptor antagonist , receptor , endothelin 1 , endothelium , pharmacology , vascular smooth muscle , antagonist , smooth muscle

The role of endothelin (ET)-1 in maintenance of basal vascular tone has been demonstrated by local and systemic vasodilatation to endothelin receptor antagonists in humans. Although the constrictor effects mediated by the vascular smooth muscle ET(A) receptors are clear, the contribution from endothelial and vascular smooth muscle ET(B) receptors remains to be defined. The present study, in human forearm resistance vessels in vivo, was designed to further investigate the physiological function of ET(A) and ET(B) receptor subtypes in human blood vessels and determine the mechanism underlying the vasodilatation to the ET(A)-selective receptor antagonist BQ-123.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research